Program Description & Educational Objectives

In this activity, experts in urology discuss a practical approach to the clinical recognition of lower urinary tract symptoms with a focus on OAB. The faculty will also review the various pharmacologic and nonpharmacologic treatments for OAB, and provide strategies to improve patient outcomes.

Upon completion of this activity, participants will be able to:

• Readily recognize, and be better able to screen for, lower urinary tract symptoms (LUTS) in men and women
• Employ pharmacologic and nonpharmacologic interventions in the overall management of patients with overactive bladder (OAB)
• Provide effective patient education and counseling to improve treatment compliance and outcomes for LUTS and OAB

Target Audience

This activity has been designed to meet the educational needs of primary care physicians, gynecologists, urologists, nurses, pharmacists, and other clinicians involved in the treatment of men and women with lower urinary tract symptoms.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: November 22, 2010 - November 21, 2012
Time to Complete PeerView inReview: 45 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Interviewee

Roger Dmochowski, MD
Director, Pelvic Medicine and Reconstruction Fellowship
Department of Urology
Vanderbilt University Medical Center
Executive Physician for Patient Safety (Surgery)
Vanderbilt University Hospital
Nashville, Tennessee

Roger Dmochowski, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Astellas Pharma Global Development, Inc.; Contura International A/S; and Pfizer Inc.

Interviewees

Matt T. Rosenberg, MD
Medical Director
Mid-Michigan Health Centers
Department of Family Medicine
Foote Health System
Jackson, Michigan

Matt T. Rosenberg, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Astellas Pharma Global Development, Inc.; Bayer HealthCare Pharmaceuticals Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Ortho-McNeil, Inc.; Pfizer Inc; and Watson Pharmaceuticals, Inc.
Speakers Bureau participant with Allergan, Inc.; Astellas Pharma Global Development, Inc.; Bayer HealthCare Pharmaceuticals Inc.; Forest Laboratories, Inc.; GlaxoSmithKline; Ortho-McNeil, Inc.; Pfizer Inc; and Watson Pharmaceuticals, Inc.
Advisory Board for Allergan, Inc.; Astellas Pharma Global Development, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc; Shionogi Inc.; and Watson Pharmaceuticals, Inc.
Other Financial or Material Support from Editorial Involvement in the International Journal of Clinical Practice.

Eric S. Rovner, MD
Professor of Urology
Director, Section of Female Urology, Neurourology and Urodynamics
Department of Urology
Medical University of South Carolina
Charleston, South Carolina

Eric S. Rovner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Pfizer Inc; and Tengion.
Grant/Research Support from Allergan, Inc.; Contura International A/S; Johnson & Johnson Services, Inc.; Pfizer Inc; Solace Therapeutics; Tengion; and The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/National Institutes of Health (NIH).
Speakers Bureau participant with Allergan, Inc.; Pfizer Inc; and Tengion.
Honorarium from Astellas Pharma Global Development, Inc.
Advisory Board for Allergan, Inc.; Medtronic, Inc.; OCEANA Therapeutics, Inc.; Pfizer Inc; and Solace Therapeutics.

Content Director

Regina Janesko, MS
PVI, PeerView Institute for Medical Education, Inc.

Regina Janesko, MS, currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Interview-Based CME
Purdue University College of Pharmacy designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Performance Improvement CME
Purdue University College of Pharmacy designates this educational activity for a maximum of 20.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education (CNEP-09, 06/01/2011) is an approved provider of continuing nursing education by the Indiana State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 0.75 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

Pharmacists

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-10-261-H01-P, 0.75 contact hours (0.075 CEUs).
Release Date: November 22, 2010 Expiration Date: November 21, 2012.

This CME/CNE/CPE activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported through an independent educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.